Elacestrant - Radius Health

Drug Profile

Elacestrant - Radius Health

Alternative Names: RAD 1901

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Developer Radius Health Inc.
  • Class Antineoplastics; Osteoporosis therapies; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Selective estrogen receptor degraders; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Vasomotor symptoms
  • Phase I Breast cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Vasomotor-symptoms(In volunteers) in Netherlands (PO)
  • 18 Oct 2017 Radius Health plans a phase II trial for Breast cancer (Metastatic disease, Monotherapy) in USA in early 2018
  • 18 Oct 2017 Elacestrant receives Fast Track designation for Breast cancer [PO] (Late-stage disease, Metastatic disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top